How a drug gets to market
Why is one drug $900 and its identical twin $4? The answer is almost always its place in the approval-and-protection lifecycle. Understand that arc and most of drug pricing stops being surprising.
The brand path: a New Drug Application
A brand-new drug reaches the market through an NDA (New Drug Application). The manufacturer runs years of clinical trials proving the drug is safe and effective, the FDA reviews it, and — if approved — the company can sell it. That investment is enormous, so the law hands the innovator a period of protection where no one can copy it.
Two kinds of protection: patents and exclusivity
People blur these together, but they're different:
- Patents are granted by the Patent Office (not the FDA), can be filed years before approval, and protect the molecule, formulation, or use. They can be litigated and sometimes invalidated.
- Exclusivity is granted by the FDA at approval and blocks competitors for a set window (e.g. 5 years for a new chemical entity, 7 for an orphan drug, 6 months for pediatric studies).
Whichever lasts longer keeps generics out. Both are listed, per drug, in the FDA's Orange Book — the same source behind the patent and exclusivity dates on this site's drug pages.
The generic path: an Abbreviated application
Once protection ends, a generic maker files an ANDA (Abbreviated New Drug Application). The “abbreviated” part is the key: the generic doesn't have to repeat the full clinical trials. It only has to prove bioequivalence — that it delivers the same active ingredient to the body the same way. That's why generics are cheap to develop, and why they can sell for a fraction of the brand.
TE codes: are two products swappable?
The Orange Book also assigns a therapeutic equivalence (TE) code — an A means a generic is substitutable for the brand, a B means it isn't. That single letter is what our interchangeability tool turns into a plain yes/no for a pharmacist making a substitution.
Biologics are a separate world
Drugs made in living cells — insulins, monoclonal antibodies — go through a BLA (Biologics License Application) instead of an NDA. Their “generics” are called biosimilars, approved under a pathway called 351(k), and they're listed in the Purple Book rather than the Orange Book. Because biologics are complex, a biosimilar is highly similar but never a byte-for-byte copy — which is why substitution rules for them are stricter.
The patent cliff: where prices fall off
The moment protection ends, the economics flip. The first generic often enters at a modest discount, but once several manufacturers pile in, competition drives the price down 80–90% or more within a year or two. This “patent cliff” is the single biggest force in drug pricing — and, paradoxically, the setup for the next chapter.
The twist
When a generic gets too cheap, manufacturers stop wanting to make it — which is exactly how the cheapest drugs end up in shortage. The race to the bottom on price is also a race toward fragility.